Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
-0.83 (-0.88%)
After Hours: 94.08 +0.71 (0.76%)
Oct 6, 5:16PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 92.71 - 94.48
52 week 84.17 - 106.84
Open 94.24
Vol / Avg. 2.25M/2.11M
Mkt cap 252.81B
P/E 23.61
Div/yield 2.67/2.86
EPS 3.95
Shares 2.42B
Beta 0.70
Inst. own 10%
Dec 3, 2015
Novartis AG at Deutsche Bank dbAccess Pharmaceutical Corporate Day Add to calendar
Dec 2, 2015
Novartis AG at Berenberg European Conference Add to calendar
Nov 25, 2015
Novartis AG at Exane BNP Paribas SRI/ESG Conference Add to calendar
Nov 19, 2015
Novartis AG at Jefferies Global Healthcare Conference Add to calendar
Nov 10, 2015
Novartis AG at UBS European Conference Add to calendar
Nov 4, 2015
Novartis AG at Citi Global Healthcare Conference Add to calendar
Oct 27, 2015
Q3 2015 Novartis AG Earnings Release - 4:00AM EDT - Add to calendar
Sep 30, 2015
Novartis AG at Sanford C Bernstein European Strategic Decisions Conference
Sep 28, 2015
Novartis AG ESG Conference Call
Sep 17, 2015
Novartis AG at Bank of America Merrill Lynch Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 14.39% 20.00%
Operating margin 17.69% 20.68%
EBITD margin - 31.46%
Return on average assets 5.51% 8.53%
Return on average equity 9.59% 14.69%
Employees 120,000 -
CDP Score - 94 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG is a holding company. The Company is a group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Company's segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Joseph Jimenez Jr Chief Executive Officer, Member of the Executive Committee
Age: 55
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 49
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Steven Baert Head Human Resources and Member of the Executive Committee
Age: 40
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters